| Medication | Receptor Targets | Peak Weight Loss (Trials) | Wyoming 503A Access | |---|---|---|---| | Semaglutide 2.4 mg | GLP-1 | 14.9% at 68 wk (STEP-1) [2] | Yes | | Tirzepatide 15 mg | GIP + GLP-1 | 20.9% at 72 wk (SURMOUNT-1) [3] | Yes | | Retatrutide 12 mg | GIP + GLP-1 + Glucagon | 24.2% at 48 wk (Phase 2) [1] | Yes | The 24.2% result for retatrutide came at 48 weeks, a shorter trial duration than STEP-1 (68 weeks) or SURMOUNT-1 (72 weeks)
Koch A, Konig B, Luci S, Stangl GI, Eder K: Dietary oxidised fat up regulates the expression of organic cation transporters in liver and small intestine and alters carnitine concentrations in liver, muscle and plasma of rats
Probiotic supplementation might theoretically support digestive health during these dietary changes, though clinical evidence specific to GLP-1 users remains sparse
Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cells and in a variety of transformed alveolar epithelial cells
The result is a detailed report of your bodys make-up: how many pounds of fat you have, how many pounds of lean mass, and even your bone density
